Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | PGD | P52209 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.31 |
| ▸ | PGK1 | P00558 | 1/20 | 0.31 |
| ▸ | PGK2 | P07205 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20475911 | 0.98 | PDE4A (0.44) | PDE4ATSHRCYP2C9PGDFOLH1 | |
| Mucic Acid SCHEMBL6050929 | 0.82 | TSHR (0.53) | PDE4ATSHRCYP2C9PGDPGK1 | |
| Mucic Acid SCHEMBL27357924 | 0.82 | TSHR (0.53) | PDE4ATSHRCYP2C9PGDPGK1 | |
| SCHEMBL27481 | 0.79 | TSHR (0.50) | PDE4ATSHRCYP2C9PGDFOLH1 | |
| SCHEMBL20798105 | 0.79 | TSHR (0.50) | PDE4ATSHRCYP2C9PGDFOLH1 | |
| SCHEMBL5488415 | 0.79 | — | — | |
| SCHEMBL27350710 | 0.79 | PGD (0.39) | PGD | |
| SCHEMBL28185396 | 0.79 | — | — | |
| SCHEMBL28834716 | 0.79 | PGD (0.39) | PGD | |
| SCHEMBL11345790 | 0.79 | TSHR (0.64) | PDE4ATSHRCYP2C9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230087751-A1 | RECOMBINANT ADENO-ASSOCIATED VIRAL VECTORS IN PLANTS | VECPROBIO, INC. | 2023-03-23 | — | — | US | disclosed |
| EP-4100056-A1 | RECOMBINANT ADENO-ASSOCIATED VIRAL VECTORS IN PLANTS | Vecprobio, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| EP-3389619-A1 | PREPARATIONS COMPRISING CARNOSINES | Symrise AG (DE) | 2018-10-24 | — | — | EP | disclosed |
| EP-3389621-A1 | EMULSIONS HAVING UV SUNSCREEN FACTORS AND CARNOSINES | Symrise AG (DE) | 2018-10-24 | — | — | EP | disclosed |
| WO-2017101976-A1 | PREPARATIONS COMPRISING CARNOSINES | SYMRISE AG (DE) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017102971-A1 | EMULSIONS HAVING UV SUNSCREEN FACTORS AND CARNOSINES | SYMRISE AG (DE) | 2017-06-22 | — | — | WO | disclosed |
| EP-2028944-B1 | COMPOSITION FOR REDUCING BAKING LOSSES | BAYER IP GMBH (DE) | 2016-08-03 | — | — | EP | disclosed |
| US-8673584-B2 | Inhibitor scaffold for the inhibition of the enzyme phosphoenolpyruvate carboxykinase | UNIVERSITY OF KANSAS (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130109031-A1 | INHIBITOR SCAFFOLD FOR THE INHIBITION OF THE ENZYME PHOSPHOENOLPYRUVATE CARBOXYKINASE | FLORIDA MEMORIAL UNIVERSITY (US) | 2013-05-02 | — | — | US | disclosed |
| EP-2028943-B1 | USE OF MODIFIED WHEAT FLOUR FOR REDUCING BAKING LOSSES | BAYER CROPSCIENCE AG (DE) | 2013-04-03 | — | — | EP | disclosed |
| WO-2007134878-A1 | COMPOSITION FOR REDUCING BAKING LOSSES | BAYER CROPSCIENCE AG (DE) | 2007-11-29 | — | — | WO | disclosed |
| WO-2005053721-A1 | ANTIOXIDANT PREPARATION FOR ORAL AND/OR TOPICAL APPLICATION | COGNIS IP MANAGEMENT GMBH (DE) | 2005-06-16 | — | — | WO | disclosed |
| EP-1541158-A1 | Antioxydant composition for oral or topical administration | Cognis Deutschland GmbH & Co. KG (DE) | 2005-06-15 | — | — | EP | disclosed |
| US-20050095305-A1 | Anti-aging agents | COGNIS IBERIA S.L. (ES) | 2005-05-05 | — | — | US | disclosed |
| US-20040142007-A1 | Cosmetic preparations containing an extract of germinating plants | COGNIS FRANCE S.A. (FR) | 2004-07-22 | — | — | US | disclosed |
| EP-1392237-A1 | COSMETIC PREPARATIONS CONTAINING AN EXTRACT OF GERMINATING PLANTS | Cognis France, S.A.S. (FR) | 2004-03-03 | — | — | EP | disclosed |
| WO-2003043595-A1 | ANTI-AGING AGENTS | COGNIS IBERIA, S.L. (ES) | 2003-05-30 | — | — | WO | disclosed |
| EP-1314420-A1 | Anti-ageing composition | Cognis Iberia, S.L. (ES) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002098385-A1 | COSMETIC PREPARATIONS CONTAINING AN EXTRACT OF GERMINATING PLANTS | COGNIS FRANCE S.A. (FR) | 2002-12-12 | — | — | WO | disclosed |
| EP-1262167-A1 | Cosmetic preparations containing an extract from germinating plants | Cognis France S.A. (FR) | 2002-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050095305-A1 | Anti-aging agents | GLA, CUTA, LIMS1 | PDE4A 2669/4885TSHR 3801/4885CYP2C9 4534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.